Xigduo (dapagliflozin + metformin): first SGLT2 inhibitor combination tablet

Xigduo (dapagliflozin + metformin) has been launched for the treatment of type II diabetes.

The initial dose of Xigduo (dapagliflozin + metformin) should correspond to the patient's current metfomin dose
The initial dose of Xigduo (dapagliflozin + metformin) should correspond to the patient's current metfomin dose

The twice-daily combination tablet, launched by Bristol-Myers Squibb and AstraZeneca, contains the sodium-glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, and the biguanide, metformin.

Xigduo is licensed for use alongside diet and exercise to treat type II diabetes in adults who are inadequately controlled on metformin alone, inadequately controlled on other hypoglycaemic agents (including insulin) plus metformin, or currently taking the combination as separate tablets.

Xigduo is given as a single tablet twice daily and is available in two strengths: dapagliflozin 5mg/metformin 850mg and dapagliflozin 5mg/metformin 1g. Prescribers should select the initial dose of Xigduo based on the patient's current metformin dose. 

If Xigduo is to be added to a regimen containing insulin or a sulfonylurea, prescribers should consider reducing the dose of insulin and/or sulfonylurea to reduce the risk of hypoglycaemia.

View Xigduo drug record

Further information: BMS/AstraZeneca

Follow MIMS on Twitter

Sign up for MIMS bulletins


Read these next

SGLT2 inhibitors: risk of diabetic ketoacidosis

SGLT2 inhibitors: risk of diabetic ketoacidosis

Patients receiving SGLT2 inhibitors (canagliflozin,...

Metformin use in renal impairment extended

Metformin use in renal impairment extended

Metformin can now be used in patients with moderate...

Xultophy: first insulin/incretin mimetic combination launched

Xultophy: first insulin/incretin mimetic combination launched

Xultophy is a prefilled pen containing a fixed-ratio...

Canagliflozin approved by NICE for diabetes

Canagliflozin approved by NICE for diabetes

NICE has approved canagliflozin (Invokana) for use...

Invokana: new SGLT2 inhibitor for type II diabetes

Invokana: new SGLT2 inhibitor for type II diabetes

Janssen-Cilag has launched Invokana (canagliflozin)...

Forxiga: first in new class of diabetes treatments

Forxiga: first in new class of diabetes treatments

The SGLT2 inhibitor dapagliflozin (Forxiga) has been...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.